102 related articles for article (PubMed ID: 11734308)
1. Overcoming drug resistance: targeting more than one site.
Karp JE; Mookerjee BP
Leuk Res; 2002 Jan; 26(1):107-9. PubMed ID: 11734308
[No Abstract] [Full Text] [Related]
2. Molecular mechanisms of drug resistance in acute myeloid leukaemia.
McLornan DP; McMullin MF; Johnston P; Longley DB
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):363-77. PubMed ID: 17539744
[TBL] [Abstract][Full Text] [Related]
3. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.
Bonhoure E; Pchejetski D; Aouali N; Morjani H; Levade T; Kohama T; Cuvillier O
Leukemia; 2006 Jan; 20(1):95-102. PubMed ID: 16281067
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.
Sonneveld P
Eur J Cancer; 1996 Jun; 32A(6):1062-9. PubMed ID: 8763348
[No Abstract] [Full Text] [Related]
5. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
Larson RA
Leukemia; 2003 Mar; 17(3):488-91. PubMed ID: 12646935
[No Abstract] [Full Text] [Related]
6. Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis.
Hassan HT; Freund M
Eur J Cancer; 1995 Oct; 31A(11):1883-4. PubMed ID: 8541118
[No Abstract] [Full Text] [Related]
7. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
Banker DE; Cooper JJ; Fennell DA; Willman CL; Appelbaum FR; Cotter FE
Leuk Res; 2002 Jan; 26(1):91-106. PubMed ID: 11734307
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of multidrug resistance in AML: current insights.
Baer MR
Clin Adv Hematol Oncol; 2005 Dec; 3(12):910-2. PubMed ID: 16555430
[No Abstract] [Full Text] [Related]
9. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
10. PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
Jakubikova J; Duraj J; Hunakova L; Chorvath B; Sedlak J
Neoplasma; 2002; 49(4):231-6. PubMed ID: 12382020
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy resistance in acute myeloid leukaemia.
Sonneveld P; List AF
Best Pract Res Clin Haematol; 2001 Mar; 14(1):211-33. PubMed ID: 11355932
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
14. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
15. Inhibited apoptosis and drug resistance in acute myeloid leukaemia.
Smith BD; Bambach BJ; Vala MS; Barber JP; Enger C; Brodsky RA; Burke PJ; Gore SD; Jones RJ
Br J Haematol; 1998 Sep; 102(4):1042-9. PubMed ID: 9734656
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents.
Tonks A; Pearn L; Mills KI; Burnett AK; Darley RL
Leukemia; 2006 Oct; 20(10):1883-5. PubMed ID: 16932340
[No Abstract] [Full Text] [Related]
17. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.
Walter RB; Raden BW; Thompson J; Flowers DA; Kiem HP; Bernstein ID; Linenberger ML
Leukemia; 2004 Nov; 18(11):1914-7. PubMed ID: 15385942
[No Abstract] [Full Text] [Related]
18. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells.
Queiroz KC; Ruela-de-Sousa RR; Fuhler GM; Aberson HL; Ferreira CV; Peppelenbosch MP; Spek CA
Oncogene; 2010 Dec; 29(48):6314-22. PubMed ID: 20802532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
